Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:108c
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 108C
Character Range: 59124–64194

108C  Vaccine                                                                                                                                                                                                                                                                                MenQuadfi®         Injection (0.5mL)                                                                 Each 0.5mL dose contains:                                                                                                                                                                                                                                                                                                                                      For persons that the circumstances in (a) and (b) of column 2 of this item apply:
      Meningococcal Neisseria meningitidis, Meningococcal polysaccharide serogroups A, C, W‑135 and Y conjugate serogroups A, C, W and Y                                                                                                                                                                                                                                                              1.     Meningococcal polysaccharide* group A 10.0 µg/dose                                                                                                                                                                                                                                                                                                       1.     1 dose
      Circumstances                                                                                                                                                                                                                                                                                                                                                                                   2.     Meningococcal polysaccharide* group C 10.0 µg/dose
      Vaccine may be provided to:                                                                                                                                                                                                                                                                                                                                                                     3.     Meningococcal polysaccharide* group Y 10.0 µg/dose                                                                                                                                                                                                                                                                                                  For persons that the circumstances in (c), (d) or (e) of column 2 of this item apply:
       (a) a child who is 12 months old; or                                                                                                                                                                                                                                                                                                                                                           4.     Meningococcal polysaccharide* group W‑135 10.0 µg/dose
       (b) a person who is at least 14 years old but less than 20 years of age; or                                                                                                                                                                                                                                                                                                                * Each of the four polysaccharides is conjugated to tetanus toxoid (approximately 55 µg /dose)
       (c) a person aged at least 12 months old who has congenital or acquired asplenia (e.g. splenectomy); or hyposplenia); or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2 doses of a primary course plus booster doses as described in the circumstances set out in subsection 7(1B).
       (d) a person aged at least 12 months old who has complement deficiency; or
       (e) a person aged at least 12 months old undergoing eculizumab treatment; or
       (f) a person who undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab.